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Abstract
Background: Probiotic yeast has become a field of interest to scientists in recent years.
Methods: Conventional cultural method was employed to isolate and identify yeast and standard methods were
used to determine different probiotic attributes, antimicrobial and antioxidant properties.
Results: This study reports potential probiotic properties of a strain of S. cerevisiae IFST 062013 isolated from fruit.
The isolate is tolerant to a wide range of temperature and pH, high concentration of bile salt and NaCl, gastric
juice, intestinal environment, α-amylase, trypsin and lysozyme. It can produce organic acid and showed resistance
against tetracycline, ampicillin, gentamycin, penicillin, polymixin B and nalidixic acid. It can assimilate cholesterol,
can produce killer toxin, vitamin B12, glutathione, siderophore and strong biofilm. It showed moderate
auto-aggregation ability and cell surface hydrophobicity. The isolate can produce enzymes such as amylase,
protease, lipase, cellulose, but unable to produce galactosidase. The isolate can’t produce gelatinase and DNase.
The isolate showed moderate anti-microbial activity against bacteria and fungi and cell lysate showed better
antimicrobial activity than whole cell and culture supernatant. Again, the isolate showed better anti-bacterial activity
against gram negative bacteria than gram positive. The isolate showed strong antioxidant activity, reducing power,
nitric oxide and hydroxyl radical scavenging activity, significant brine shrimp cytotoxicity and acute toxicity and
metal ion chelating activity. The isolate did not induce any detectable change in general health of mice upon oral
toxicity testing and found to be safe in mouse model. The isolate improve lymphocyte proliferation and cytokine
production in treated mice.
Conclusions: Such isolate could be potential as probiotic to be used therapeutically.
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Background
Probiotics are a group of organism those confer health
benefit to consumers [1]. To be used as probiotic, an
organism should possess several attributes such as adhe-
sive ability, acid and H2O2 production ability [2], bile
tolerance and significant antibacterial activity and immu-
nomodulatory activity [3] and must be non-pathogenic
[4, 5]. Microorganisms that are probiotic to humans in-
clude yeasts, bacilli, Escherichia coli, enterococci, and
the more commonly used bifidobacteria and lactic acid
bacteria, such as lactobacilli, lactococci and streptococci
[6]. Previous reports involving both In vitro and in vivo
studies have indicated that Saccharomyces boulardii is
able to prevent intestinal infection caused by Escherichia
coli, Salmonella typhimurium, Staphylococcus aureus,
Pseudomonas aeruginosa, Proteus vulgaris, Yersinia
enterocolitica and Candida albicans [7]. But probiotics
properties of Saccharomyces cerevisiae haven’t been
explored that much.
Saccharomyces cerevisiae is a unicellular yeast and one
of the most explored organism in terms of industrial ap-
plications and genetic studies [8]. Several previous stud-
ies showed that members of Saccharomyces genus can
possess anti-bacterial and probiotic properties [9].
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Several studies have also been reported with the use of
yeasts (S. boulardii or S. cerevisiae) as a potential bio-
therapeutic agent (probiotic) for the treatment of mi-
crobes associated diarrhea and colitis [10]. Anti-bacterial
capability of S. cerevisiae might be due to production of
extracellular protease [11], secretion of inhibitory pro-
teins, stimulation of immunoglobulin A [12], acquisition
and elimination of secreted toxins [13], killer toxins, sul-
fur di oxide etc. [14]. Foods such as milk, fermented
foods, fruits, etc. are an important source of probiotic
Saccharomyces cerevisiae [14, 15].
No such study has been performed in Bangladesh to
assess the probiotic potential of indigenous Saccharomy-
ces cerevisiae. This study aims to determine the probiotic
properties of a putative probiotic yeast strain, S. cerevi-
siae IFST 062013.
Methods
Isolation and identification of S. cerevisiae IFST 062013
The yeast isolates, S. cerevisiae IFST 062013 was isolated
from fruit and characterized morphologically and
biochemically according to Fakruddin et al. [16]. Carbo-
hydrate (Glucose, xylose, sucrose, fructose, galactose,
lactose, maltose, trehalose, ribose, rhamnose, mannitol
and dextrose) utilization capability of the isolate was
determined according to Forouhandeh et al. [17]. Phylo-
genetic identification on the basis of sequencing of
highly variable region of the fungal 5.8S rDNA gene was
performed as described in Fakruddin et al. [16].
Stress tolerance of yeast isolate
Sodium chloride tolerance of the yeast strains was per-
formed according to Fakruddin et al. [18]. Sensitivity of
yeast strains to oral and intestinal enzymes (lysozyme,
trypsin and α-amylase) was studied as per Nowroozi et
al. [19]. In vitro survival potential of the yeast isolates in
simulated gastric environment (aqueous solution con-
taining 3 g/l pepsin, and 5 g/l NaCl, pH 2.0) was deter-
mined according to Fietto et al. [20]. pH tolerance was
determined according to Fakruddin et al. [21]. Bile salt
tolerance of the isolates was investigated according to
Kim et al. [22]. Thermotolerance of the yeast strains was
determined according to Fakruddin et al. [14]. Organic
acid production was determined according to
Chowdhury et al. [4]. Antibiotic resistance of the isolate
was determined by the standard agar disc diffusion
technique described by Kirby-Bauer [23] and interpret-
ation were taken from the CLSI standards [24].
Probiotic properties
Cholesterol assimilation assay was performed as per
Liong and Shah [25]. Cell surface hydrophobicity and
auto-aggregation ability was performed according to Syal
and Vohra [26]. Activities of enzymes (amylase, protease,
lipase, galactosidase and cellulase) were determined ac-
cording to Kim et al. [22] and production of gelatinase
and DNase was determined according to Gupta and
Malik [27]. Killer toxin production was observed accord-
ing to Fakruddin et al. [16]. Vitamin B12 production by
the isolate was assayed according to Bishnoi et al. [28].
The reduced glutathione (GSH) content in the yeast
extracts and autolysates were determined according to
Hassan [29]. Siderophore production was screened
according to Sourabh et al. [15]. Biofilm formation assay
was performed according to Li et al. [30].
Preparation of S. cerevisiae extracts and autolysates
Yeast extracts from the yeast strains were prepared
according to Ali et al. [31] and yeast autolysates were
prepared according to Hassan [29].
Antibacterial and anti-fungal activity
Anti-microbial (anti-bacterial and anti-fungal) activity of
whole cell was performed by agar overlay method [32]
and of cell culture supernatant and cell lysate was per-
formed by well diffusion method [33]. Antibacterial
activity was further characterized by determining
whether bacteriostatic or bactericidal according to
Chowdhury et al. [34]. All the test isolates of bacteria
and fungi were taken from culture collection pool of
Industrial Microbiology Laboratory, IFST, BCSIR,
Dhaka.
Antioxidant and toxicity properties
Total antioxidant capacity of yeast extracts and autoly-
sates was assayed by the phosphomolybdenum method
as described by Kumaran and Karunakaran [35]. The
reducing power of yeast extracts and autolysates was de-
termined by the method of Mathew and Abraham [36].
The antioxidant activity based on the scavenging activity
of the stable DPPH free radical, was determined by the
method described by Fakruddin et al. [37]. The scaven-
ging activity of nitric oxide was determined by the
method described by Kumaran and Karunakaran [35].
Hydroxyl radical scavenging activity was assayed by the
method described by Nagai et al. [38]. Brine shrimp
cytotoxicity assay was performed according to Fakruddin
et al. [16] and acute toxicity was done according to
Kabir et al. [39]. The ability of yeast extracts and autoly-
sates to chelate ferrous ion was determined using the
method described by Oboh et al. [40].
Safety evaluation of S. cerevisiae IFST 062013
Twelve swiss albino mice aged 5–6 weeks were divided
into two treatment groups designated as C and T (6 mice
in each group). In order to assess the safety of the putative
probiotic isolate, S. cerevisiae IFST 062013, a single dose
of 150 μl (~109 cfu) S. cerevisiae IFST 062013 were
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administered orally to each of the test group mice. Mice
of the control group were fed with sterile PBS. After feed-
ing, mice were monitored daily for 14 days to observe any
changes in their activities, behavior and general health. In-
dividual body weight was recorded daily using a balance
[41]. In addition, the feces of mice were collected to enu-
merate the total numbers of S. cerevisiae and enterobac-
teria on day 0, 7 and 14. After 14 days. YPD agar was used
for enumeration of S. cerevisiae and MacConkey agar was
used for enumeration of enterobacteria [42]. Blood sam-
ples were collected for biomarker analysis, including
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), alkaline phosphatase (ALP) and total
cholesterol of the serum. Blood sample was also used to
check fungaemia. The growth rate (GR), spleen weight
index and liver weight ratio were calculated according to
Kantachote et al. [43].
Immuno-Modulatory activity of S. cerevisiae IFST 062013
Lymphocyte proliferation assay was performed according
to Ren et al. [44]. Production of cytokines (IFN-α, IFN-γ,
IL-10) was measured according to Ren et al. [44]. Gene
expression of TLR-2, interferon (IFN)-γ, IL-4, Foxp3 and
transforming growth factor (TGF)-β in intestinal mucosa
was determined according to Zhu et al. [45].
Statistical analysis
One way analysis of variance (ANOVA) was used to
compare the results of the probiotic and control groups.
Means, standard deviations and significant differences at
p value < 0.05 were presented.
Result
Isolation and identification
Based on the colony characteristics (white and creamy
texture) ovoid microscope shape, the presence of asco-
spore and budding pattern (multipolar), the selected iso-
late was found to belong Saccharomyces type unicellular
ascomycete. Ascospores formation by the yeast isolate
was detected for indication of the ascomycetous yeast.
The yeast isolate can produce pseudomycelium and
showed in a filamentous form under microscope and
can utilize glucose, fructose, sucrose, maltose and trehal-
ose but failed to grow on lactose and xylose, rhamnose,
raffinose and arabinose, which is characteristic of
Saccharomyces cerevisiae [46]. 5.8 s rDNA sequencing
revealed the identity of the isolate to be Saccharomyces
cerevisiae (Accession no- HM134859.1).
Stress tolerance
Stress tolerance of the S. cerevisiae IFST 062013 isolate
is shown in Fig. 1. The isolate able to survive in a wide
range of temperature and pH with optimum conditions
of 37 °C and pH 5.0. It can tolerate high concentration
of bile salt and NaCl, gastric juice, intestinal environ-
ment, alpha-amylase, trypsin and lysozyme. It can also
produce organic acid (2.25% after 90 h incubation). The
isolate showed resistance to tetracycline, trimethoprim-
sulphamethoxazole, ampicillin, gentamycin, penicillin,
nitrofurantoin, polymixin B and nalidixic acid (Fig. 1).
Probiotic properties
Probiotic properties of the isolate are shown in Table 1.
The isolate can assimilate 33% cholesterol and produced
different enzymes such as amylase (84 unit/g cell), prote-
ase (1760 unit/g cell), lipase (77 unit/g cell), cellulase (39
unit/g cell) and galactosidase as well as siderophore,
killer toxin and strong biofilm. It can also produce
4.48 mg/100 ml total glutathione and 61.34% auto-
aggregation ability (Table 1).
Antibacterial and anti-fungal activity
Antibacterial activity of whole cells, culture supernatant
and cell lysate of the isolated yeast is shown in Table 2.
Comparing with doxycycline (30 μg/disc), the isolate
showed moderate antibacterial activity. Antifungal activ-
ity of whole cells, culture supernatant and cell lysate of
the isolated yeast is shown in Table 3. Comparing with
fluconazole (100 μg/disc), the isolate showed moderate
antifungal activity. In general, cell lysate showed better
anti-bacterial and anti-fungal effect. Anti-bacterial effect
of the isolate was better against gram negative pathogens
than gram positive.
Antioxidant activity and toxicity
Antioxidant activities and toxic properties of the isolate
is shown in Fig. 2. The isolate was found to possess dif-
ferent beneficial activity. The isolate showed significant
reducing power, DPPH scavenging activity, nitric oxide
scavenging and hydroxyl radical scavenging activity
(comparing with ascorbic acid). Strong brine shrimp
cytotoxicity and acute toxicity was shown by the isolate
(100% lethality at 500 μg/ml in case of cytotoxicity and
150 mg/kg in case of acute toxicity). The chelating effect
of the ferrous ions of the yeast isolate is presented in
Table 4. The isolate exhibited the ability of iron binding.
Safety evaluation of S. cerevisiae IFST 062013
There were no significant differences in general health
status between probiotic fed mice and control mice
(Fig. 3a). No diarrheal death was observed and no S. cer-
evisiae detected in blood as well. Fungaemia was not
observed in blood samples of the mouse. AST, ALT and
ALP content in blood were similar and cholesterol con-
tent in treated mice blood is lower than the control mice
(Fig. 3b). Enterobacteria and S. cerevisiae count in the
feces of treated and control mice was almost similar dur-
ing the observation period (Fig. 3c). The growth rate of
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Fig. 1 Stress tolerance of the S. cerevisiae IFST062013 isolate
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treated mice found to be almost similar (difference non-
significant) and the spleen weight index and liver weight
ratio are almost similar in both groups (treated and con-
trol) (Fig. 3d).
Immuno-modulatory activity
Results indicate that the S. cerevisiae strain could stimu-
late a T-lymphocyte specific proliferative response. Pro-
liferation index was significantly increased by the strains
in a dose dependent manner (Fig. 4a). To evaluate the
effects of S. cerevisiae IFST062013 on T-cell responses,
the concentrations of IFN-α, IFN-γand IL-10 in mouse
serum were examined. There was no significant differ-
ence in the induction of IFN-α production during the
experimental period between treated and control group
(Fig. 4b). IFN-γlevels in the serum showed no significant
differences on day 10, but were, however, significantly
increased by S. cerevisiae IFST062013 (248 pg/mL) at
the higher dose (5x109 CFU/mouse) compared with the
control group (189 pg/mL) on day 20 (P < 0.05). IL-10
levels were significantly increased by S. cerevisiae
IFST062013 (711 pg/mL) at the higher dose on day 10,
compared with the control group (635 pg/mL) (P < 0.05),
but a more prominent effect was found for probiotic
treated group 751 pg/mL) compared with the control
group (637 pg/mL) on day 20 (P < 0.01). Gene expression
of cytokines (TLR-2, IFN-γ, IL-4, Foxp3 and TGF-β) in
intestinal mucosa was determined. Expression of TLR-2
and IFN-γ was increased in mice treated the isolate in a
dose dependent manner. In contrary, the expression of
Foxp3, TGF-β and IL-4 was decreased (Fig. 4e).
Discussion
Saccharomyces cerevisiae is one of the most studied mi-
croorganisms and for long has been used in different
biotechnological applications due to its better fermen-
tation capability. Besides industrial applications, pro-
biotic and health benefit potential of yeast has also
been reported in recent times [47]. Probiotics are
defined as the viable microorganisms that exhibit a
beneficial effect on health of the host by improving its
intestinal microbial balance. S. cerevisiae and S. boular-
dii are clinically proven yeasts being used as a human
probiotic and has shown to positively influence host’s
health by antimicrobial effect, nutritional effect, inacti-
vation of bacterial toxins, quorum sensing, trophic
effects, immuno-modulatory effects, anti-inflammatory
effects, cell restitution and maintenance of epithelial
barrier integrity [48].
Table 2 Antibacterial activity of the yeast isolate
Test organism Source ID (ATCC) Zone diameter (mm)
Yeast isolate Doxycycline
Whole cell Culture supernatant Cell lysate
Gram positive B. subtilis 11774 7 5.1 11.6 21
S. aureus 25923 7.5 4.9 10.3 24
B. cereus 10876 7 6.1 9.4 12
B. polymyxa 842 8.5 5.9 11.4 21
B. megaterium 13578 7 5.4 9.8 28
E. faecalis 29212 6.5 5.3 10.4 19
Gram negative S. typhi 65154 11.5 8.3 14.8 27
S. flexneri 12022 12.0 7.9 15.2 15
K. pneumoniae 13883 10.5 7.5 13.7 22
P. vulgaris 13315 10 8.1 15.1 17
E. coli 25922 11 8.7 14.9 19
V. cholerae 15748 13.5 9.6 16.3 26
P. aeruginosa 27853 12.5 9.1 16.1 21
Table 1 Different probiotic properties of the yeast isolate
Property S. cerevisiae isolate
Cholesterol assimilation 33%
Enzyme activity assay amylase 84 unit/g cell
protease 1760 unit/g cell
lipase 77 unit/g cell
cellulase 39 unit/g cell
Killer toxin production +
total Glutathione production 1.48 mg/100 ml yeast
Galactosidase enzyme production -
Production of siderophore +
Biofilm formation Strong (SBF > 1)
Auto-aggregation ability 61.34%
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In this study a potential probiotic yeast strain (S. cere-
visiae IFST 062013) was isolated from fruit and identi-
fied and characterized as Saccharomyces cerevisiae on
the basis of morphological and biochemical characteris-
tics and phylogenetic analysis. Many other studies
reported probiotic yeast isolated from different samples
[5, 14, 15, 49, 50]. Al Zubaidy and Khidhr [51] also iden-
tified Saccharomyces cerevisiae var. bouldardii from
fruits with probiotic properties (antimicrobial activity,
bile salt and gastric acid tolerance). Syal and Vohra [52]
reported probiotic attributes of Geotrichum klebahnii, a
yeast like fungus isolated from cheese.
Table 3 In-vitro antifungal activity of CHET and fluconazole
Organism Source ID (DSM) Zone diameter (mm)
Yeast Fluconazole
Whole cell Culture supernatant Cell lysate
A. ustus 63535 16.5 14.6 19.5 45
A. niger 737 27.2 24.3 33.4 65
A. ochraceus 824 21.6 18.4 24.1 41
P. chrysogenum 1075 23.5 19.7 25.3 48
R. oryzae 2200 19.7 17.5 22.7 46
Fig. 2 Pharmacological activity of the S. cerevisiae IFST062013 isolate
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To be a successful probiotic, any microorganisms must
have the capability to be tolerant to stresses that prevail
inside human body. The isolate can grow in a wide range
of temperature and pH while optimum growth at 370C
and pH 5.0. It also possesses tolerance to bile salt, high
NaCl, simulated gastric juice, intestinal environment, α-
amylase, trypsin and lysozyme (Fig. 1). Syal and Vohra
[26] reported yeast isolates that can survive in low pH
and high bile salt concentration. It can produce organic
acid and showed resistance against tetracycline, ampicil-
lin, gentamycin, penicillin, polymixin B and nalidixic
acid. The resistance of the yeast strain to antibiotics
make it suitable for use in patients undergoing antibiotic
treatment [52]. Higher resistance to antibiotic provides
the yeast strain advantage over bacteria for therapeutic
use.
The isolate pose desirable properties to be a potential
probiotic. It can assimilate cholesterol (33%), can pro-
duce killer toxin, vitamin B12, glutathione, siderophore
and strong biofilm. Vitamins play key role in numerous
metabolic processes of the body and yeasts have been re-
ported to be able to produce vitamins, especially vitamin
B complex, which is a distinctive advantage for yeast to
be used as a probiotic over bacteria [52]. Dubash et al.
[53] reported a number of yeast strains belonging to
Sachharomyces cerevisiae, Candida pintolopesii,
Candida tropicalis, Pichia anomala and Dekkera spp.
with killer toxin activity. It showed moderate auto-
aggregation ability and cell surface hydrophobicity.
Auto-aggregation and cell surface hydrophobility is very
important property of a potential probiotic as these
properties are involved in adhesion of the microorgan-
isms to intestinal epithelial cells of patients [54]. To
provide health benefits to patients by improving nutrient
utilization within the intestine, a probiotic should have
the ability to produce related enzymes [55]. The isolate
can produce enzymes such as amylase, protease, lipase,
cellulose, but unable to produce galactosidase. The iso-
late don’t produce gelatinase and DNase indicating its
safety to be used for human patients as most of the
pathogenic microorganisms produce these enzymes as
part of their pathogenesis [26]. Cholesterol assimilation
by yeast with probiotic attributes has also been reported
by Chen et al. [53]. Syal and Vohra [26] reported yeast
isolates that showed high auto-aggregation ability and
cell surface hydrophobicity. The isolates were able to
produce enzymes such as phytase, β-galactosidase,
L-asparaginase, protease and lipase. The isolates can
produce vitamin B12 and exopolysaccharide. The
isolates can assimilate cholesterol, don’t produce DNase
Fig. 3 Safety evaluation of S. cerevisiae IFST 062013 in mice. a comparison of body weight; b comparison of AST, ALP, ALT and cholesterol level;
c Enterobacteria and S. cerevisiae count in the feces; d comparison of liver weight and spleen weight ratio of treated and control mice




Standard EDTA Yeast isolate
1 2.5 47.86 ± 1.11 13.84 ± 0.97
2 3.5 63.24 ± 0.93 19.54 ± 1.15
3 4.5 76.15 ± 1.42 23.42 ± 0.68
4 5.5 86.34 ± 1.69 28.33 ± 1.43
5 6.5 91.25 ± 0.75 33.77 ± 1.85
Values are expressed as mean ± SD of three parallel measurements
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and gelatinase. Sourabh et al. [15] reported probiotic
yeast with surface hydrophobicity and autoaggregation.
One of the most desirable properties of probiotic
yeasts is the anti-bacterial activity of yeasts against
human pathogens. The isolate showed moderate anti-
microbial activity against bacteria and fungi in compari-
son with standard antibiotic (Doxycycline for bacteria
and fluconazole for fungi). Cell lysate showed better
antimicrobial activity than whole cell and culture super-
natant. Again, the isolate showed better anti-bacterial
activity against gram negative bacteria than gram
positive. Culture supernatant showed least anti-
microbial activity indicating that the anti-microbial com-
pounds are not extracellular, rather cell bound. Raj-
kowska et al. [56] reported probiotic yeast strains
(belonging to S. cerevisiae and S. boulardii) which
showed antagonistic activity against human pathogens
such as Listeria monocytogenes, Salmonella typhimur-
ium, Pseudomonas aeruginosa, Escherichia coli and En-
terococcus faecalis. Roostita et al. [14] reported yeast
strains with antimicrobial activity against Pseudomonas
aerugenes, Staphylococcus aureus and Escherichia coli.
Fig. 4 Immuno-modulatory activity of the S. cerevisiae IFST062013. a T-lymphocyte proliferation; b IFN-α, c IFN-γ, d IL-10 production in serum of
treated and control mice; e Gene expression of cytokines (TLR-2, IFN-γ, IL-4, Foxp3 and TGF-β) in intestinal mucosa
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Syal and Vohra [26] isolated yeast with antimicrobial ac-
tivity against E. coli, Salmonella sp., Staphylococcus aur-
eus, Vibrio cholerae and Pseudomonas sp. Further studies
on antimicrobial activity of the yeast isolate against other
species of pathogenic bacteria and fungi are needed.
The isolate showed strong antioxidant activity, redu-
cing power, nitric oxide and hydroxyl radical scavenging
activity, significant brine shrimp cytotoxicity and acute
toxicity (Fig. 2) and metal ion chelating activity (Table 4).
Foligne et al. [42] reported yeast possessing significant
anti-inflammatory activity in mice. Antioxidant activity
of yeast has also been reported by Chen et al. [54]. Has-
san [29] reported two yeast isolate, whose cell autoly-
sates showed antioxidant and immunostimulating
activity such as reducing power, DPPH radical scaven-
ging, nitric oxide scavenging, hydroxyl radical scaven-
ging and metal ion chelating activities. Sourabh et al.
[15] reported probiotic yeast with antioxidant properties,
DPPH free radical scavenging activity and siderophore
production ability. The isolate also showed strong metal
chelating activity, an essential property for antioxidant
activity. Hassan [29] has reported probiotic Saccharomy-
ces cerevisiae with strong metal ion chelating activity.
Safety assessment is an important criterion to select
any potential probiotic for therapeutic applications.
To assess the safety of S. cerevisiae IFST 062013, oral
toxicity testing in mice was conducted. After 14 days
of post-ingestions period, there were no significant
differences in behavior or activity of the mice and no
diarrheal death. No S. cerevisiae was detected in
blood samples which indicate that the isolate don’t
pose the ability to infiltrate areas outside the intes-
tine. AST level provides a general estimation about
any cellular injury occurred as its level increases in
case of disease & cellular injury. On the other hand,
ALT more specifically indicates liver cell damage &
higher serum cholesterol. Increased ALP has been
linked with increased osteoblastic activity & lack of
bile flow & higher serum cholesterol [41]. Blood sam-
ple analysis also showed that AST, ALP and ALT con-
tent is almost similar in both treated and control
group mice. But cholesterol content in treated group
mice were lower than control group mice further en-
suring the isolate’s ability to assimilate cholesterol.
These observations indicate that the isolate do not in-
duce any gross acute oral toxicity on general health,
growth and development of mice. There were no sig-
nificant differences in numbers of enterobacteria and
S. cerevisiae in the feces of treated group and control
group mice throughout the 14 day observation period,
which indicate that the isolate can persist in the in-
testines. Growth rate of the treated group mice was
almost similar to that of the control mice. There were
no significant difference between spleen weight index
and liver weight ratio of the treated group and con-
trol group mice. These results indicate that the isolate
cannot induce any systemic infections in mice and is
non-invasive.
To test the effect of S. cerevisiae IFST062013 on the
cellular immune response, we examined splenocyte pro-
liferation. On day 10, the spleen lymphocyte prolifera-
tion capacity was significantly increased in the S.
cerevisiae-treated groups when compared with the ConA
control group (P < 0.04). The SI values of the higher
dose groups (5x109 CFU/mouse) reached their max-
imum values and were higher than for the moderate
dose groups (5x108 CFU/mouse) (P < 0.01). On day 20,
the results showed a similar trend. These results indicate
that the probiotic S. cerevisiae strain could stimulate a
T-lymphocyte specific proliferative response and could
potentiate humoral immunity and cell-mediated immun-
ity and consequently have potential antitumor activity.
Cytokines play an important role in the development of
immune response, we evaluated the effect of the strain
on the production of pro-inflammatory cytokines IFN-α
and IFN-γ, and the anti-inflammatory cytokine IL-10.
IFN-γinduces cell-mediated and inflammatory immune
responses. Our results showed that the probiotic strain
simultaneously induced pro- and anti-inflammatory
mediators and consequently helped to maintain a
balance between Th1 and Th2 type cytokines, which is
important for host immunity. The probiotic strain mod-
ulates gene expression of cytokines in dose dependent-
manner (Fig. 4).
Conclusion
The Saccharomyces cerevisiae IFST 062013 isolate
showed promising probiotic activities and possessed
comparable attributes with other reported probiotic
yeasts. Continuous screening for selection of probiotic
strains with even better attributes should be carried out.
Before therapeutic application, further research should
be done to ensure safety and efficiency of the potential
probiotic yeast.
Abbreviation
ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate
aminotransferase; Cfu: Colony forming unit; CLSI: Clinical and Laboratory
Standards Institute; DNA: Deoxyribo nucleic acid; DPPH: 2,2-diphenyl-1-
picrylhydrazyl; GSH: Glutathione; PBS: Phosphate buffered saline;
PCR: Polymerase chain reaction; YPD: Yeast extract-Peptone-Dextrose agar;
µg: Micro gram
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